CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Paliperidone extended release (ER)drug
Likely dose
Paliperidone extended release (ER) 3 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01387542
NCT01387542Phase 4Completed
CompareCT.gov

An Open-label, PRospective Study to Evaluate Social Function and Overall Improvement of Paliperidone ER Treatment in Thai Schizophrenia PatieNT (PRESENT)

Janssen-Cilag Ltd.,Thailand·interventional·Posted Jul 4, 2011·Updated Mar 5, 2013

In Brief

A Phase 4 clinical trial evaluating Paliperidone extended release (ER) for Schizophrenia. Completed, enrolled 40 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (ER) treatment in Thai schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesThailand
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 4, 2011
Enrollment StartAug 1, 2009
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.0 years ago

Interventions

Paliperidone extended release (ER)drug

Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks